Cargando…
Strategies for translating proteomics discoveries into drug discovery for dementia
Tauopathies, diseases characterized by neuropathological aggregates of tau including Alzheimer’s disease and subtypes of frontotemporal dementia, make up the vast majority of dementia cases. Although there have been recent developments in tauopathy biomarkers and disease-modifying treatments, ongoin...
Autores principales: | Halder, Aditi, Drummond, Eleanor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479849/ https://www.ncbi.nlm.nih.gov/pubmed/37488854 http://dx.doi.org/10.4103/1673-5374.373681 |
Ejemplares similares
-
Translational Medicine and Drug Discovery
por: Tworkoski, Kathryn
Publicado: (2011) -
Bioinformatics in translational drug discovery
por: Wooller, Sarah K., et al.
Publicado: (2017) -
Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias
por: Carlyle, Becky C., et al.
Publicado: (2018) -
Drug Discovery and Development Targeting Dementia
por: Zagórska, Agnieszka, et al.
Publicado: (2023) -
Senolytic drugs: from discovery to translation
por: Kirkland, J. L., et al.
Publicado: (2020)